Cytek Biosciences
CTKB
74 hedge funds and large institutions have $515M invested in Cytek Biosciences in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 7 closing their positions.
314% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 7
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
42% more funds holding
Funds holding: 52 → 74 (+22)
9.38% more ownership
Funds ownership: 26.2% → 35.59% (+9.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less capital invested
Capital invested by funds: $572M → $515M (-$57.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$51M |
| 3 |
BlackRock
New York
|
+$50.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.2M |
| 5 |
D.E. Shaw & Co
New York
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$31.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$29M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$28.1M |
| 4 |
MGM
Miura Global Management
New York
|
-$10.3M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$6.53M |
CTKB Hedge Fund Activity: Q1 2022 in Review
74 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2022, worth a combined $515M — down 10% from $572M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CTKB positions and 7 closed out — a net gain of 22 holders — while 33 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $69.4M. The largest seller was OrbiMed, exiting entirely with an estimated $31.4M sold.
- 74 institutional investors held Cytek Biosciences (CTKB) as of Q1 2022, up from 52 in Q4 2021.
- Funds reported $515M of Cytek Biosciences stock for Q1 2022, down 10% quarter-over-quarter.
- 29 funds opened new Cytek Biosciences positions in Q1 2022 and 7 closed out, a net change of +22 holders.
- The largest Cytek Biosciences buyer in Q1 2022 was Vanguard Group, an estimated $69.4M added.
- The largest Cytek Biosciences seller in Q1 2022 was OrbiMed, an estimated $31.4M sold.
Based on aggregated 13F filings for Q1 2022.